New antibody drug targets skin scarring in transplant survivors

NCT ID NCT07011810

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called axatilimab for people whose skin becomes thick and hard (sclerotic) after a donor stem cell transplant, a condition called chronic graft-versus-host disease. The drug aims to block immune signals that cause inflammation and scarring. About 50 adults will receive the treatment to see if it improves skin flexibility and reduces disability.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST-DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome chronic graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC GRAFT-VERSUS-HOST-DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Dana-Farber Cancer Institute
NOT_YET_RECRUITING

Boston, Massachusetts, 02115, United States

Contact
Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Moffitt Cancer Center
NOT_YET_RECRUITING

Tampa, Florida, 33612, United States

Contact